It was reported that genetic and epigenetic aberrations of CDKN2A resulted in enhanced carcinogenesis and poor prognosis in various cancers, such as ovarian cancer, lymphoma, and prostate cancer, etc [28, 29]. This evidence concerns the gene CDKN2A and prostate cancer.